levofloxacin has been researched along with carbapenems in 35 studies
| Studies (levofloxacin) | Trials (levofloxacin) | Recent Studies (post-2010) (levofloxacin) | Studies (carbapenems) | Trials (carbapenems) | Recent Studies (post-2010) (carbapenems) |
|---|---|---|---|---|---|
| 4,346 | 581 | 2,209 | 7,355 | 147 | 5,277 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.86) | 18.2507 |
| 2000's | 9 (25.71) | 29.6817 |
| 2010's | 16 (45.71) | 24.3611 |
| 2020's | 9 (25.71) | 2.80 |
| Authors | Studies |
|---|---|
| Hikida, M; Igarashi, A; Itahashi, K; Kitamura, M; Shiba, T | 1 |
| Iwashima, A; Kiguchi, T; Sato, K; Yamaguchi, M | 1 |
| Burgess, DS; Frei, CR; Moczygemba, LR | 1 |
| Hashimoto, H; Horii, T; Maekawa, M; Muramatsu, H; Takeshita, A | 1 |
| Engel, AE; Glass, D; Li, C; Wexler, HM | 1 |
| Chen, WH; Hsueh, PR; Luh, KT | 1 |
| Miyagi, T; Nakashima, T; Shigehara, K; Shimamura, M | 1 |
| Gutiérrez, F; Hernández, I; Masiá, M; Matoses, C; Murcia, A; Navarro, A; Padilla, S; Romero, I; Sánchez, V | 1 |
| Naber, KG; Redman, R; Wagenlehner, C; Wagenlehner, FM; Weidner, W | 1 |
| Hedrich, D; Kaniga, K; Kotey, P; Llorens, L; Naber, KG; Redman, R | 1 |
| Damiao, R; Davies, T; Kaniga, K; Kotey, P; Naber, KG; Redman, R | 1 |
| Fukuchi, K; Gomi, K; Takahashi, N; Wakuta, R; Yamaguchi, F | 1 |
| Baba, S; Fujita, T; Iwamura, M; Kimura, M; Kurosaka, S; Matsumoto, K; Minamida, S; Satoh, T; Tabata, K; Tsumura, H | 1 |
| Hsueh, PR; Lee, YJ; Lin, YC; Liu, HY; Wu, HH | 1 |
| Davies, TA; He, W; Lynch, AS; Queenan, AM | 1 |
| Kurtinecz, M; Li, G; Mitrani-Gold, FS; Mundy, LM; Singh, KP; Tomayko, JF; Wetherington, J | 1 |
| Crandon, JL; Nicolau, DP; Nordmann, P; Wiskirchen, DE | 1 |
| Fang, X; Gong, M; Xia, J; Xu, Y; Zhang, D; Zhou, Y | 1 |
| Mataraci-Kara, E; Ozbek Celik, B; Yilmaz, M | 1 |
| Fu, Y; Liu, R; Pan, Z; Zhang, P; Zhou, H; Zhou, J | 1 |
| Hackel, MA; Hoban, DJ; Karlowsky, JA; Lob, SH; Sahm, DF | 1 |
| Hirai, J; Koizumi, Y; Mikamo, H; Nishiyama, N; Sakanashi, D; Suematsu, H; Sugimoto, N; Yamagishi, Y | 1 |
| Bruns, T; Büning, J; Fichtner-Feigl, S; Kruis, W; Maaser, C; Preiß, JC; Reuken, PA; Schmelz, R; Stallmach, A; Teich, N | 1 |
| Ebihara, Y; Imai, K; Kodana, M; Maeda, T; Maesaki, S; Mitsutake, K; Murakami, T; Sakai, J; Taji, Y; Tarumoto, N; Watanabe, N; Yamaguchi, T | 1 |
| Ahmad, N; Ahuja, SD; Akkerman, OW; Alffenaar, JC; Anderson, LF; Baghaei, P; Bang, D; Barry, PM; Bastos, ML; Behera, D; Benedetti, A; Bisson, GP; Boeree, MJ; Bonnet, M; Brode, SK; Brust, JCM; Cai, Y; Caumes, E; Cegielski, JP; Centis, R; Chan, ED; Chan, PC; Chang, KC; Charles, M; Cirule, A; D'Ambrosio, L; Dalcolmo, MP; de Vries, G; Dheda, K; Esmail, A; Flood, J; Fox, GJ; Fréchet-Jachym, M; Fregona, G; Gayoso, R; Gegia, M; Gler, MT; Gu, S; Guglielmetti, L; Holtz, TH; Hughes, J; Isaakidis, P; Jarlsberg, L; Kempker, RR; Keshavjee, S; Khan, FA; Kipiani, M; Koenig, SP; Koh, WJ; Kritski, A; Kuksa, L; Kvasnovsky, CL; Kwak, N; Lan, Z; Lange, C; Laniado-Laborín, R; Lee, M; Leimane, V; Leung, CC; Leung, EC; Li, PZ; Lowenthal, P; Maciel, EL; Marks, SM; Mase, S; Mbuagbaw, L; Menzies, D; Migliori, GB; Milanov, V; Miller, AC; Mitnick, CD; Modongo, C; Mohr, E; Monedero, I; Nahid, P; Ndjeka, N; O'Donnell, MR; Padayatchi, N; Palmero, D; Pape, JW; Podewils, LJ; Reynolds, I; Riekstina, V; Robert, J; Rodriguez, M; Schnippel, K; Seaworth, B; Seung, KJ; Shim, TS; Singla, R; Smith, SE; Sotgiu, G; Sukhbaatar, G; Tabarsi, P; Tiberi, S; Trajman, A; Trieu, L; Udwadia, ZF; van der Werf, TS; Veziris, N; Viiklepp, P; Vilbrun, SC; Walsh, K; Westenhouse, J; Yew, WW; Yim, JJ; Zetola, NM; Zignol, M | 1 |
| Link, I; Loose, M; Naber, KG; Wagenlehner, FME | 1 |
| Fan, X; Fu, Y; Li, C; Li, J; Wang, Y; Yu, L; Zhang, J; Zhang, X; Zhao, Y | 1 |
| Goto, K; Itoh, H; Kai, M; Kitano, T; Ohchi, Y; Suzuki, Y; Tanaka, R; Tatsuta, R; Yasuda, N | 1 |
| Atsuda, K; Azuma, S; Hoshiyama, T; Inagaki, R; Komatsu, T; Mochida, S; Nihonyanagi, S; Sato, Y; Seto, Y; Takayama, Y; Wada, T | 1 |
| Bezruk, VV; Bulyk, TS; Buriak, OH; Godovanets, OS; Honcharuk, LM; Hresko, MD; Hresko, MM; Makarova, OV; Pervozvanska, OI; Rynzhuk, LV; Sheremet, MI; Shkrobanets, ID; Velia, MI; Voytkevich, NI; Yurkiv, OI; Yurniuk, SV | 1 |
| Jia, P; Jia, X; Kang, M; Li, R; Li, X; Liu, X; Xu, Y; Yang, Q; Yu, W; Zhu, Y | 1 |
| Guo, S; Li, X; Li, Y; Shao, J; Tian, M; Tong, H; Wei, M; Xu, B; Yan, B | 1 |
| Assanelli, AA; Bernardi, M; Carletti, S; Carrabba, MG; Castagna, A; Ciceri, F; Clerici, D; Corti, C; Erbella, F; Farina, F; Galli, L; Giglio, F; Greco, R; Liberatore, C; Lorentino, F; Lugli, AP; Lupo Stanghellini, MT; Mancini, N; Mastaglio, S; Nitti, R; Oltolini, C; Peccatori, J; Poli, A; Ripa, M; Ruggeri, A; Scarpellini, P; Tassan Din, C; Xue, E | 1 |
| Aguirre-Burciaga, E; Alcaraz-Espejel, M; Avilés-Benítez, LK; Barlandas-Rendón, NRE; Barroso-Herrera-Y-Cairo, IE; Bocanegra-Ibarias, P; Bolado-Martinez, E; Camacho-Ortiz, A; Carnalla-Barajas, MN; Cetina-Umaña, CM; Cobos-Canul, DI; Colin, C; Couoh-May, CA; Duarte, L; Echaniz-Aviles, G; Escalante-Armenta, SP; Feliciano-Guzmán, JM; Garza-González, E; Gil, M; Gómez-Choel, AC; Hernández-Cordova, IY; Hernández-Dueñas, AMDR; Huirache-Villalobos, GS; López, D; Lopez, L; López-García, M; López-Gutiérrez, E; López-Jácome, LE; Martínez-Gamboa, RA; Mena-Ramirez, JP; Molina, A; Mora-Jiménez, I; Morales-de-la-Peña, CT; Morfin-Otero, R; Munoz, S; Newton-Sánchez, OA; Ortiz-Brizuela, E; Padilla-Ibarra, C; Peralta-Catalán, R; Perez-Ricardez, ML; Ponce-de-Leon, A; Quevedo-Ramos, MA; Quintanilla-Cazares, LJ; Rincón-Zuno, J; Rivera-Ferreira, MC; Rodriguez-Noriega, E; Rodriguez-Zulueta, P; Rojas-Larios, F; Romero, D; Ruiz-Gamboa, LA; Soto, A; Tinoco, JC; Velázquez-Acosta, MDC; Zubiate, H | 1 |
| Chacko, S; Maheshwari, TK; Murdeshwar, S; Sheikh, RY | 1 |
3 review(s) available for levofloxacin and carbapenems
| Article | Year |
|---|---|
Systematic review and meta-analysis of antimicrobial treatment effect estimation in complicated urinary tract infection.
Topics: Anti-Bacterial Agents; Carbapenems; Cilastatin; Cilastatin, Imipenem Drug Combination; Clinical Trials as Topic; Databases, Bibliographic; Doripenem; Drug Combinations; Female; Humans; Imipenem; Levofloxacin; Male; Research Design; Treatment Outcome; Urinary Tract Infections | 2013 |
Invasive pneumococcal disease caused by mucoid serotype 3 Streptococcus pneumoniae: a case report and literature review.
Topics: Aged; Anti-Bacterial Agents; Carbapenems; Cephalosporins; Erythromycin; Hospitalization; Humans; Japan; Levofloxacin; Male; Microbial Sensitivity Tests; Penicillins; Pneumonia, Pneumococcal; Serogroup; Serotyping; Streptococcus pneumoniae; Treatment Outcome | 2017 |
Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis.
Topics: Amikacin; Antitubercular Agents; Capreomycin; Carbapenems; Clofazimine; Diarylquinolines; Drug Therapy, Combination; Fluoroquinolones; Humans; Kanamycin; Levofloxacin; Linezolid; Moxifloxacin; Recurrence; Treatment Failure; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2018 |
4 trial(s) available for levofloxacin and carbapenems
| Article | Year |
|---|---|
Limited efficacy of a nonrestricted intervention on antimicrobial prescription of commonly used antibiotics in the hospital setting: results of a randomized controlled trial.
Topics: Aged; Anti-Bacterial Agents; Carbapenems; Counseling; Drug Prescriptions; Drug Utilization; Female; Guideline Adherence; Hospitals; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Organizational Policy; Vancomycin | 2008 |
Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteria; Carbapenems; Doripenem; Double-Blind Method; Female; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Ofloxacin; Prospective Studies; Pyelonephritis; Urinary Tract Infections | 2009 |
Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Carbapenems; Doripenem; Double-Blind Method; Female; Humans; Infusions, Intravenous; Levofloxacin; Male; Ofloxacin; Pyelonephritis; Urinary Tract Infections | 2009 |
Safety and efficacy of intravenous doripenem for the treatment of complicated urinary tract infections and pyelonephritis.
Topics: Aged; Anti-Infective Agents, Urinary; Carbapenems; Doripenem; Double-Blind Method; Female; Genotype; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Injections, Intravenous; Levofloxacin; Male; Middle Aged; Ofloxacin; Pyelonephritis; Treatment Outcome; Urinary Tract Infections | 2010 |
28 other study(ies) available for levofloxacin and carbapenems
| Article | Year |
|---|---|
In vitro antibacterial activity of LJC 11,036, an active metabolite of L-084, a new oral carbapenem antibiotic with potent antipneumococcal activity.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Carrier Proteins; Cefdinir; Cephalosporins; Dipeptidases; Drug Stability; Escherichia coli Proteins; Hexosyltransferases; Imipenem; Lactams; Levofloxacin; Microbial Sensitivity Tests; Muramoylpentapeptide Carboxypeptidase; Ofloxacin; Penicillin-Binding Proteins; Peptidoglycan Glycosyltransferase; Peptidyl Transferases; Protein Binding; Serine-Type D-Ala-D-Ala Carboxypeptidase; Thienamycins | 1999 |
[Isolation-frequency and antibiotic susceptibility of Streptococcus pneumoniae, Haemophilus influenzae, and Pseudomonas aeruginosa isolated in regional core hospitals in the Nagaoka district of Niigata Prefecture (changes for 3 years)].
Topics: Anti-Infective Agents; Carbapenems; Ciprofloxacin; Drug Resistance, Bacterial; Haemophilus influenzae; Hospitals, Urban; Humans; Japan; Levofloxacin; Ofloxacin; Penicillin G; Pseudomonas aeruginosa; Streptococcus pneumoniae; Time Factors | 2004 |
Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases.
Topics: Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Carbapenems; Ciprofloxacin; Drug Resistance, Bacterial; Ertapenem; Escherichia coli; Fluoroquinolones; Gatifloxacin; Humans; Imipenem; Klebsiella pneumoniae; Lactams; Levofloxacin; Meropenem; Microbial Sensitivity Tests; Models, Biological; Monte Carlo Method; Ofloxacin; Thienamycins | 2004 |
Characterization of fluoroquinolone and carbapenem susceptibilities in clinical isolates of levofloxacin-resistant Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Carbapenems; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Mutation; Ofloxacin; Porins; Pseudomonas aeruginosa; Pseudomonas Infections | 2005 |
In vitro activities of doripenem and comparator agents against 364 anaerobic clinical isolates.
Topics: Anti-Bacterial Agents; Bacteria, Anaerobic; beta-Lactams; Carbapenems; Doripenem; Ertapenem; Humans; Imipenem; Levofloxacin; Meropenem; Microbial Sensitivity Tests; Ofloxacin; Thienamycins | 2005 |
Relationships between antimicrobial use and antimicrobial resistance in Gram-negative bacteria causing nosocomial infections from 1991-2003 at a university hospital in Taiwan.
Topics: Aminoglycosides; Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Carbapenems; Cephalosporins; Cross Infection; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Hospitals, University; Humans; Incidence; Length of Stay; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Taiwan | 2005 |
Acute bacterial prostatitis after transrectal prostate needle biopsy: clinical analysis.
Topics: Aged; Anti-Bacterial Agents; Biopsy, Needle; Blood; Carbapenems; Cephalosporins; Drug Resistance, Bacterial; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Ofloxacin; Prostate; Prostatitis; Ultrasound, High-Intensity Focused, Transrectal; Urinary Tract Infections; Urine | 2008 |
[Validity of using imipenem as a representative carbapenems and levofloxacin as a representative fluoroquinolones in antibiotics susceptibility test for enterobacteriaceae].
Topics: Anti-Bacterial Agents; Carbapenems; Drug Resistance, Bacterial; Enterobacteriaceae; Fluoroquinolones; Imipenem; Levofloxacin; Ofloxacin | 2011 |
Prevalence of fluoroquinolone-resistant Escherichia coli before and incidence of acute bacterial prostatitis after prostate biopsy.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibiotic Prophylaxis; Biopsy, Needle; Carbapenems; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Feces; Fluoroquinolones; Humans; Incidence; Levofloxacin; Male; Middle Aged; Ofloxacin; Prevalence; Prostate; Prostatitis; Rectum | 2011 |
Correlation between levofloxacin consumption and the incidence of nosocomial infections due to fluoroquinolone-resistant Escherichia coli.
Topics: Anti-Bacterial Agents; Carbapenems; Cephalosporins; Cross Infection; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Humans; Levofloxacin; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2016 |
Assessment of the combination of doripenem plus a fluoroquinolone against non-susceptible Acinetobacter baumannii isolates from nosocomial pneumonia patients.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Animals; Carbapenems; Ciprofloxacin; Doripenem; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Synergism; Drug Therapy, Combination; Female; Levofloxacin; Mice; Ofloxacin; Pneumonia, Ventilator-Associated; Random Allocation; Survival Analysis | 2013 |
Efficacy of humanized carbapenem and ceftazidime regimens against Enterobacteriaceae producing OXA-48 carbapenemase in a murine infection model.
Topics: Animals; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Carbapenems; Ceftazidime; Disease Models, Animal; Doripenem; Ertapenem; Humans; Klebsiella pneumoniae; Levofloxacin; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests | 2014 |
A retrospective analysis of carbapenem-resistant Acinetobacter baumannii-mediated nosocomial pneumonia and the in vitro therapeutic benefit of cefoperazone/sulbactam.
Topics: Acinetobacter baumannii; Aged; Aged, 80 and over; Anti-Bacterial Agents; C-Reactive Protein; Carbapenems; Cefoperazone; Cross Infection; Drug Combinations; Drug Resistance, Multiple, Bacterial; Drug Synergism; Female; Humans; Levofloxacin; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Minocycline; Pneumonia, Bacterial; Retrospective Studies; Sulbactam; Thienamycins | 2014 |
Effects of various antibiotics alone or in combination with doripenem against Klebsiella pneumoniae strains isolated in an intensive care unit.
Topics: Carbapenems; Colistin; Doripenem; Dose-Response Relationship, Drug; Drug Combinations; Humans; Intensive Care Units; Klebsiella Infections; Klebsiella pneumoniae; Levofloxacin; Minocycline; Rifampin; Tigecycline; Tobramycin | 2014 |
Combination of Tigecycline and Levofloxacin for Successful Treatment of Nosocomial Pneumonia Caused by New Delhi Metallo-β-Lactamase-1-Producing Raoultella planticola.
Topics: Aged; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Cross Infection; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Enterobacteriaceae; Enterobacteriaceae Infections; Feces; Gene Expression; Humans; Levofloxacin; Male; Minocycline; Plasmids; Polymerase Chain Reaction; Sputum; Tigecycline; Treatment Outcome | 2017 |
Antimicrobial susceptibility of Gram-negative ESKAPE pathogens isolated from hospitalized patients with intra-abdominal and urinary tract infections in Asia-Pacific countries: SMART 2013-2015.
Topics: Acinetobacter baumannii; Amikacin; Anti-Infective Agents; Asia; beta-Lactamases; beta-Lactams; Carbapenems; Cephalosporins; Drug Resistance, Multiple, Bacterial; Enterobacter; Ertapenem; Gram-Negative Bacteria; Hospitalization; Humans; Imipenem; Intraabdominal Infections; Klebsiella pneumoniae; Levofloxacin; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Urinary Tract Infections | 2017 |
Microbial Spectrum of Intra-Abdominal Abscesses in Perforating Crohn's Disease: Results from a Prospective German Registry.
Topics: Abdominal Abscess; Adult; Anti-Bacterial Agents; Antifungal Agents; beta-Lactamase Inhibitors; Candida albicans; Carbapenems; Cephalosporins; Crohn Disease; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterococcus; Female; Germany; Humans; Immunosuppressive Agents; Intestinal Perforation; Length of Stay; Levofloxacin; Male; Penicillins; Prospective Studies; Quinolones; Registries; Streptococcus; Young Adult | 2018 |
First report of the isolation of bla
Topics: Aminoglycosides; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Cephalosporins; Colistin; Drug Resistance, Multiple, Bacterial; Enterobacter cloacae; Enterobacteriaceae Infections; Humans; Japan; Levofloxacin; Microbial Sensitivity Tests | 2018 |
Carbapenem-Containing Combination Antibiotic Therapy against Carbapenem-Resistant Uropathogenic
Topics: Anti-Bacterial Agents; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Drug Resistance, Multiple, Bacterial; Ertapenem; Fosfomycin; Humans; Levofloxacin; Microbial Sensitivity Tests; Rifampin; Urinary Tract Infections | 2019 |
The efficacy of colistin monotherapy versus combination therapy with other antimicrobials against carbapenem-resistant
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Carbapenems; Colistin; Drug Resistance, Multiple, Bacterial; Drug Synergism; Drug Therapy, Combination; Humans; Levofloxacin; Meropenem; Microbial Sensitivity Tests | 2020 |
Simultaneous quantification of plasma levels of 12 antimicrobial agents including carbapenem, anti-methicillin-resistant Staphylococcus aureus agent, quinolone and azole used in intensive care unit using UHPLC-MS/MS method.
Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Azoles; Carbapenems; Chromatography, High Pressure Liquid; Ciprofloxacin; Daptomycin; Doripenem; Drug Monitoring; Female; Fluconazole; Fluoroquinolones; Humans; Intensive Care Units; Levofloxacin; Linezolid; Male; Meropenem; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Oxazines; Oxazolidinones; Quinolones; Tandem Mass Spectrometry; Tetrazoles; Voriconazole | 2021 |
Evaluation of a carbapenem antimicrobial stewardship program and clinical outcomes in a Japanese hospital.
Topics: Anti-Bacterial Agents; Antimicrobial Stewardship; Carbapenems; Fluoroquinolones; Hospitals; Humans; Japan; Levofloxacin; Meropenem; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa | 2022 |
Management of antibacterial therapy of infectious and inflammatory diseases of the urinary tract in children and regional peculiarities during the COVID-19 pandemic.
Topics: Adolescent; Anti-Bacterial Agents; Carbapenems; Child; Child, Preschool; COVID-19 Drug Treatment; Doxycycline; Humans; Imipenem; Infant; Infant, Newborn; Levofloxacin; Microbial Sensitivity Tests; Pandemics; Urinary Tract; Urinary Tract Infections | 2022 |
Emergence of a Novel NDM-5-Producing Sequence Type 4523 Klebsiella pneumoniae Strain Causing Bloodstream Infection in China.
Topics: Aged; Amikacin; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Cephalosporins; Colistin; Female; Formaldehyde; Humans; Klebsiella Infections; Klebsiella pneumoniae; Levofloxacin; Microbial Sensitivity Tests; Multilocus Sequence Typing; Phylogeny; Plasmids; Sepsis | 2022 |
Sitafloxacin pharmacokinetics/pharmacodynamics against multidrug-resistant bacteria in a dynamic urinary tract infection in vitro model.
Topics: Anti-Bacterial Agents; Bacteria; Carbapenems; Escherichia coli; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Urinary Tract Infections; Vancomycin | 2022 |
Levofloxacin prophylaxis vs no prophylaxis in patients with neutropenia within an endemic country for carbapenem-resistant GNB.
Topics: Anti-Infective Agents; Carbapenems; Cohort Studies; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Levofloxacin; Neutropenia; Piperacillin; Retrospective Studies; Tazobactam; Transplantation, Homologous | 2023 |
Bacterial incidence and drug resistance from pathogens recovered from blood, cerebrospinal and pleural fluids in 2019-2020. Results of the Invifar network.
Topics: Anti-Bacterial Agents; Bacteria; Carbapenems; Drug Resistance; Escherichia coli; Humans; Incidence; Levofloxacin; Retrospective Studies; Vancomycin | 2023 |
Microbiological Spectrum and Antibiogram of Urinary Tract Infection in a Tertiary Care Center from the Kingdom of Bahrain.
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Bahrain; beta-Lactamases; Carbapenems; Ciprofloxacin; Escherichia coli; Female; Humans; Klebsiella pneumoniae; Levofloxacin; Male; Microbial Sensitivity Tests; Retrospective Studies; Tertiary Care Centers; Trimethoprim, Sulfamethoxazole Drug Combination; Urinary Tract Infections | 2022 |